Join HSANZ
At the recent very successful HSANZ New Zealand branch meeting in Palmerston North an AGM was held at which there was a discussion about paying tribute to contributors to haematology in NZ. It was agreed to name a session at the annual branch meeting after them in their respective field. It was decided after a vote that the morphology session could be re-named every 10 years after a respected colleague. Edward Theakston who died recently, was to be the new memorial session. An obituary by Anna Ruskova was included in the last HSANZ newsletter.
As New Zealand councillor, Annette Neylon was asked to write a letter to his widow explaining this and HSANZ Council endorsed the proposal unanimously.
The Fellowships are open to researcher and clinicians who are
Full eligibility criteria and application details can be found on the Leukaemia Foundation website
https://www.leukaemia.org.au/research/current-funding-opportunities/research-fellowships/
Make new connections and get your clinical questions answered at Highlights of ASH® in Asia-Pacific this March! Our small meeting is the ideal environment to meet your future colleagues and collaborators. Join us for:
You are cordially invited to attend the HSANZ New Zealand Annual Branch Meeting from 2-4 April 2023.
The program and registration information is attached or click www.spconferences.co.nz/hsanz-2023
Haematology Society of Australia and New Zealand is a partner with ASH for Highlights of ASH in Asia Pacific.
ASH, in partnership with the Hematology and Blood Transfusion Society of Vietnam, are delighted to bring you the official Highlights of ASH® in Asia-Pacific on March 10-11, 2023, in Hanoi, Vietnam. Join us for small-group discussions about the most influential research presented at the 2022 ASH annual meeting, tailored to the Asia-Pacific region. You will:
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, speakers will review major topics in stem cell transplantation and cell therapy, highlighting how key advances are addressing the current challenges in stem cell transplantation. This webinar features Professor Thomas Luft who is a consultant haematology and oncologist and the taskforce leader for allogeneic haematopoietic stem cell transplant and myelodysplastic syndromes at the Heidelberg University Hospital. Following the completion of his PhD studies at the University of Melbourne, Prof Luft completed post-doctoral fellowships at the Ludwig Institute for Cancer Research in Melbourne as well as the German Cancer Research Centre, where is now the Head of the “Adaptive Immune Regulation” research group. Prof Luft’s research has focused on endothelial complications following allogeneic haematopoietic stem cell transplantation leading to several publications in high impact factor journals and several presentations at international conferences. In this webinar, Prof Luft will be speaking on the early endothelial complications after haematopoeitic stem cell transplant.
Speaker:
Professor Thomas Luft – University of Heidelberg, Heidelberg University Hospital
When: Monday 21 November 2022, 5pm AEDT
For more information click here
Link to webinar:
Link to CBTCT website for all webinar recordings:
The Haematology Society of Australia and New Zealand (HSANZ) and Maddie Riewoldt’s Vision (Maddie’s Vision) are pleased to announce their partnership and commitment to awarding a doctoral scholarship to an Australian or New Zealand applicant demonstrating outstanding merit in both acquired and inherited bone marrow failure syndromes and related disorders.
Maddie’s Vision PhD Research Priorities
This year, Maddie’s Vision and HSANZ will award a PhD scholarship to a successful applicant, whose work contributes to innovative scientific research towards finding new treatments and ultimately cures for both acquired and inherited bone marrow failure syndromes, and aligns with the research priorities of the Maddie’s Vision 5 Pillars of Research:
· Comprehensive clinical data and sample collection on current and newly diagnosed patients with BMF· Genomic and epigenomic control of HSC survival, growth and differentiation · The components and control of the HSC niche · Abnormalities of immune function · Monitoring and predictors of prognosis, response to treatment and disease evolution
Maddie’s Vision and HSANZ PhD Scholarship will:· Provide total funding of no more than $130,000 comprising: · a. a stipend of $40,333 per annum. · b. a consumable budget of up to $3,000 per annum. · Fund each PhD Scholarship for no more than three years of full-time study. · Be dependent on submission of the required annual report to HSANZ and Maddie’s Vision.
Eligibility1. Citizens or permanent residents of either Australia or New Zealand 2. Able to start the PhD in 2023 3. Willing to present their work as an abstract or oral presentation at the annual Scientific Meeting Blood or HSANZ meeting on at least one occasion throughout their Scholarship 4. Willing to participate in publicity and promotional activity organised by Maddie’s Vision5. Be a member of the Haematology Society of Australia and New Zealand www.hsanz.org.au6. Applicants may only receive one PhD scholarship or Clinical Fellowship from the HSANZ during their lifetime 7. Maddie’s Vision HSANZ PhD Scholarship is not to be held in conjunction with another Scholarship, with the exception of tuition fee exemption. If the applicant accepts another PhD scholarship to run concurrently with the Maddie’s Vision HSANZ PhD scholarship, then the Maddie’s Vision HSANZ PhD scholarship will be discontinued.
Applications must contain a:· Research Proposal (5 pages maximum including references) · CV of the applicant (3 pages maximum) · Statement of how the proposed research project directly relates to Maddie’s Vision’s research priorities, and the aims and objectives of the Haematology Society of Australia and New Zealand (1 page maximum) · Written reference from a referee familiar with the applicant’s recent work history (1 page maximum) · Research supervisor report to confirm laboratory support for the research proposal. The report should also comment on the suitability of the applicant for the proposed project and likelihood for successful completion of the project within the proposed time period
Application Procedure1. Applications must be accompanied by all relevant documentation 2. Applications must be submitted in full by midnight AEST on the closing date3. Applicants will submit one electronic (pdf) copy of their scholarship application emailed to HSANZ Office 4. Incomplete or late applications will not be considered 5. Applications will be subject to review by a committee comprised of the HSANZ Council and a representative of Maddie’s Vision. The committee’s decision is final 6. The outcome of applications will be announced mid-August 2022 7. Maddie’s Vision and HSANZ reserve the right to not award a scholarship
Download and share flyer - Final HSANZ Maddie's Vision PhD Scholarship Criteria 2022.pdf
Kindly use this coversheet with your application: MRV HSANZ PhD scholarship application coversheet.pdf
Applications Close: Sunday 6 November 2022 at 11:59 pm AEST
Submitting Electronic (pdf) Applications
Electronic applications, along with all supporting documents should be submitted as a single pdf. The pdf should be named MVHSANZ_PhD2022_[FamilyName] and submitted by email, to HSANZ at admin@hsanz.org.au and Maddie’s Vision at research@mrv.org.au
Postdoc Research Associate Cancer Immunotherapy, 0094825
Full time Fixed term until July 2023
Three positions available for Research Associates to provide their research expertise in CAR T-Cells
Base Salary $79,784 - $107,516 + 17% superannuation
About the opportunity
The University of Sydney recently appointed Professor Cameron Turtle as the CLEARbridge Chair of Cancer Immunotherapy. Professor Turtle has recently returned to Australia from Seattle where he led clinical and laboratory research teams conducting multiple investigator-initiated phase 1 clinical trials of genetically modified cellular (CAR-T cell) immunotherapies for patients with haematologic malignancies.
The School of Medical Sciences in the Faculty of Medicine and Health has an exciting opportunity for 3 early career researchers to join a newly formed research team supporting the continuation of Professor Turtle’s work in Australia. The Research Associates will be running experiments with the aim of understanding the characteristics of distinct human T-Cell subsets, the development of novel tumor immunotherapies and factors governing the immune response to cancer.
Your key responsibilities will be to:
· carry out relevant lab based research
· supervise and mentor research support staff and students
· assist with various research support requirements
· collaborate with research teams to prepare research findings for publication.
Closing date for applications 11.59pm, 12 October 2022
Please click here to apply Postdoctoral Research Associate Cancer Immunotherapy 0094825
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 17 October 2022
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, speakers will review major topics in stem cell transplantation and cell therapy, highlighting how key advances are addressing the current challenges in stem cell transplantation. This webinar features Professor Catherine Bollard, who is the current Program Director for Cell Enhancement and Technologies for Immunotherapies at the Children’s National Hospital, Associate Centre Director for Translational Research and Innovation at the GW Cancer Centre and Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at the George Washington University. Her bench and translational research has focused on improving post-transplant outcomes through developing novel cellular therapeutics, leading to over 200 peer reviewed publications and ongoing independent NIH funding for over a decade. In this webinar, Professor Bollard will be outlining the role of T cell therapies for lymphoma.
Professor Catherine Bollard – Children’s National Hospital, George Washington University
When: Friday 17 October 2022, 8am AEDT
https://bloodcelltherapy.org.au/
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 4 October 2022
When: Friday 4 October 2022, 5pm AEDT
© 2023 Haematology Society of Australia & New Zealand All Rights Reserved.
Privacy Policy
